Abstract
Introduction Larger fill volumes in peritoneal dialysis (PD) typically improve small solute clearance and water removal, and vice versa – but the relationship between intra-peritoneal volume and the capacities for solute and water transport in PD has been little studied. Here, it is proposed that this relative relationship is described by a simple ratio (Volumenew/Volumeold)2/3 up to a critical break-point volume, beyond which further volume increase is less beneficial in terms of transport.
Method To scrutinize this hypothesis, experiments were conducted in a rat model of PD alongside a retrospective analysis of clinical data from a prior study. Rats underwent PD with either three consecutive fills of 8+8+8 mL (n=10) or 12+12+12 mL (n=10), with 45-minute dwell time intervals. This approach yielded sixty estimations of water and solute transport, characterized by osmotic conductance to glucose (OCG) and solute diffusion capacities, respectively.
Results Comparative analysis of the predictive efficacy of the two models — the simple ratio versus the break-point model — was performed using Monte Carlo cross-validation. The break-point model emerged as a superior predictor for both water and solute transport, demonstrating its capability to characterize both experimental and clinical data.
Conclusion The present analysis indicates that relatively simple calculations can be used to approximate clinical effects on transport when prescribing a lower or higher fill volume to patients on PD.
Competing Interest Statement
C.M. Oberg reports research grants from Baxter Healthcare and Fresenius Medical Care, and speaker's honoraria from Boehringer-Ingelheim and Baxter Healthcare. C.M. Oberg reports a consultancy agreement with Baxter Healthcare and an advisory or leadership role with the Peritoneal Dialysis International editorial board.
Funding Statement
This study was funded by Lund University Medical Faculty Foundation (grant YF 2020-YF0056), The Inga-Britt and Arne Lundberg's Research Foundation, the Swedish Kidney Foundation, and the Crafoord Foundation (all to C.M. Oberg).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally published in Keshaviah et al. J Am Soc Nephrol 1994; 4:1820-6.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Original experimental data reported in this article have been deposited in figshare (doi: 10.6084/m9.figshare.24947982).
